In Entwicklung
Business·22.6.2026KI-Zusammenfassung
Aurobindo Pharma's US Arm Gets FTC Approval for $250 Million Lannett Acquisition
Aurobindo Pharma's US subsidiary has received FTC approval for its $250 million acquisition of Lannett Company. The deal, expected to close by June 2026, will enhance Aurobindo's complex generics and controlled substances portfolio and boost US manufacturing.
E
Economic Times